^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    1d
    AAAV0505: A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=6, Suspended, Columbia University | Recruiting --> Suspended
    Trial suspension
    |
    cyclophosphamide • NKX019
    1d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360
    Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    1d
    SZ4601: CAR-T Cell Therapy Targeting to CD19 for R/R ALL (clinicaltrials.gov)
    P1/2, N=196, Recruiting, The First Affiliated Hospital of Soochow University | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Aug 2024 --> Aug 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    1d
    Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Virginia Commonwealth University | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date • Checkpoint inhibition • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • HR negative • HER-2 negative + HR negative
    |
    Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • decitabine
    1d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    1d
    A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases (clinicaltrials.gov)
    P1, N=52, Recruiting, Kite, A Gilead Company | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor
    |
    LRP4 (LDL Receptor Related Protein 4)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    1d
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV • RG6540
    2d
    Chronic Study on the Environmentally Relevant Concentration of Cytotoxic Drug Cyclophosphamide on the Biochemical Responses of the Freshwater Mussel Lamellidens marginalis. (PubMed, Appl Biochem Biotechnol)
    A noteworthy decrease (p ≤ 0.005) in antioxidant activity was obtained in 0.5 and 5.0 µg/L of CP concentration. Overall, the present findings reveal that increased concentration of CP alters antioxidant defence mechanisms in Lamellidens marginalis.
    Journal
    |
    CAT (Catalase)
    |
    cyclophosphamide
    2d
    Linkage Between miR-218-2 (rs11134527) Genetic Polymorphism and Breast Cancer Risk: A Case-Control Study in the Bangladeshi Women. (PubMed, Health Sci Rep)
    Chemotherapy was the principal treatment (62.12%), with cyclophosphamide (69.62%), doxorubicin (53.80%), and paclitaxel (56.33%) as the most prescribed agents. Significant associations were also observed under the recessive model (AA vs. GG + AG: OR = 1.96, 95% CI = 1.0-3.86, p = 0.051) and the allelic model (A vs G: OR = 1.59, 95% CI = 1.06-2.39, p = 0.026). The miR-218-2 rs11134527 A allele confers an increased risk of breast cancer in Bangladeshi women, supporting its potential role as a population-specific genetic biomarker for susceptibility assessment.
    Journal
    |
    MIR218 (MicroRNA 218)
    |
    paclitaxel • doxorubicin hydrochloride • cyclophosphamide
    2d
    C3 Glomerulonephritis Associated With Anti-complement Factor B Antibodies Following Anti-cancer Treatment With Pembrolizumab. (PubMed, Kidney Med)
    Despite treatment with corticosteroids, plasma exchange, cyclophosphamide and eculizumab he remained dialysis-dependent. PD-1 inhibitors, such as pembrolizumab, are known to predispose to loss of tolerance and generation of autoantibodies. In this case, factor B autoantibodies were detected in association with C3GN.
    Journal
    |
    CFB (Complement Factor B)
    |
    Keytruda (pembrolizumab) • cyclophosphamide
    2d
    Protective effect of Rosmarinus officinalis L. extract against cyclophosphamide-induced testicular toxicity in rats. (PubMed, Clin Exp Reprod Med)
    Although Bax expression was reduced, the decrease was not statistically significant. In conclusion, RE appears to provide protection against CYC-induced testicular injury.
    Preclinical • Journal • IO biomarker
    |
    BAX (BCL2-associated X protein)
    |
    cyclophosphamide
    2d
    Cyclophosphamide Induces Autophagy-Dependent Ferroptosis Through Promoting ETNK1 Expression in Breast Cancer Cells. (PubMed, Drug Dev Res)
    Downregulation of ETNK1 could reverse the impacts of CTX on cell survival, ferroptosis, and autophagy both in vitro and in vivo. CTX-induced iron death dependent on autophagy in breast cancer cells by promoting the expression of ETNK1.
    Journal
    |
    ETNK1 (Ethanolamine Kinase 1) • BECN1 (Beclin 1)
    |
    cyclophosphamide